Citations 1
Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).
Watanabe, Toshiaki , Ohtsu, Atsushi , Yamazaki, Kentaro , Sunami, Eiji , Shirao, Kuniaki , Satō, Atsushi, Morita, Satoshi , Yamanaka, Takeharu , Sakamoto, Junichi , Saji, Shigetoyo, Yoshino, Takayuki , Mori, Masaki , Mizushima, Tsunekazu , Grothey, Axel , Sargent, Daniel J.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS3655-TPS3655
